UCSF Study Challenges Psychedelic Hype as Level Playing Field Comparison Shows No Advantage Over Antidepressants

UCSF research finds psychedelic-assisted therapy is no more effective than standard antidepressants when accounting for patient expectations and trial blinding.

By: AXL Media

Published: Mar 19, 2026, 4:40 AM EDT

Source: Information for this report was sourced from University of California - San Francisco

Addressing the Methodological Crisis in Psychedelic Research

The rapidly growing enthusiasm for psychedelic-assisted therapy has faced a significant scientific hurdle: the "unblinding" problem. Because substances like psilocybin and LSD produce powerful subjective experiences, participants in clinical trials almost always know whether they have received the active drug or a placebo. This awareness creates a "knowing the treatment" factor that can artificially inflate the perceived success of the drug. To solve this, a research team led by Dr. Balázs Szigeti at UCSF compared psychedelic trial data against "open-label" antidepressant trials, where patients also knew exactly what they were taking. This approach aimed to ensure both treatments benefited equally from positive patient expectations.

The Disappearance of the Psychedelic Advantage

The results of the comparative analysis were both surprising and sobering for the scientific community. When placed on a level playing field with traditional antidepressants, the supposed clinical superiority of psychedelics effectively vanished. Patients in both groups showed substantial improvement, with depression scores dropping by approximately 12 points on standard medical scales. However, there was virtually no statistical difference between the two treatments. According to Dr. Szigeti, the findings contradict the prevailing narrative that psychedelics offer a transformational leap over existing medications, suggesting instead that the two may be functionally equivalent in their therapeutic impact.

The Role of Expectation in Clinical Outcomes

The study highlights how the lack of blinding in previous psychedelic research may have skewed public and professional perceptions. In typical psychedelic trials, those who receive the drug often improve significantly because they are aware of the treatment, while those in the placebo group may experience a "nocebo" effect, feeling worse because they know they missed out. In contrast, traditional antidepressant trials often maintain better blinding, which makes the difference between the drug and placebo groups appear much smaller. When the researchers removed this variable by only looking at trials where everyone knew their treatment, the massive gap that favored magic mushrooms and LSD disappeared.